LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics
Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that
originated and continues to develop collagenase-based therapies
with a first in class collagenase-based product marketed as
XIAFLEX® in the U.S. and Xiapex® in
Europe, today named life sciences
industry veteran Kevin Buchi chief
executive officer of BioSpecifics. He will also serve on the
company's board of directors.
"We are extremely pleased to have Kevin join BioSpecifics as
chief executive officer. The board of directors believes that
Kevin's diversified life sciences leadership experience and
business acumen will drive transformative vision and strategy for
generating both near- and long-term shareholder value," said
Jenn Chao, Chair of the Executive
Search Committee.
"I am thrilled to be joining BioSpecifics. This is a unique
company with very significant opportunities to further advance its
collagenase-based therapies both commercially and clinically," said
Mr. Buchi. "There are several key milestones on the near-term
horizon including a potential third marketed indication for
XIAFLEX, with the BLA filing submitted in early September for the
treatment of cellulite, and the continued growth of the XIAFLEX
commercial franchise and development portfolio."
Mr. Buchi is currently the chairman of the board of directors at
Dicerna Pharmaceuticals and a director of Amneal Pharmaceuticals
and Benitec Biopharma Ltd. Mr. Buchi was most recently president
and chief executive officer at TetraLogic Pharmaceuticals from 2012
to 2016. Previously, he served as Impax Laboratories' interim
President and chief executive officer from December 2016 to March
2017. Earlier, he served as corporate vice president of
Global Branded Products at Teva Pharmaceutical from 2011 to
May 2012. Mr. Buchi also served as
chief executive officer of Cephalon, which was acquired by Teva in
October 2011. He had been at the
company since 1991. Mr. Buchi holds a Masters of Management degree
from the J.L. Kellogg Graduate School of Management from
Northwestern University and a B.A. in
Chemistry from Cornell University.
About BioSpecifics Technologies Corp.
BioSpecifics
Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for thirteen clinical indications
to date. Injectable collagenase is marketed as XIAFLEX® in the U.S.
for the treatment of Dupuytren's contracture and Peyronie's disease
by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX®
is also commercialized in Japan,
Europe, Canada and Australia for Dupuytren's contracture and for
Peyronie's disease in Canada,
Europe and Australia. The CCH research and development
pipeline includes several additional indications including
cellulite, adhesive capsulitis, lipomas, lateral hip fat, plantar
fibromatosis and uterine fibroids. For more information, please
visit www.biospecifics.com.
Forward-Looking Statements
This press release
includes forward-looking statements within the meaning of, and made
pursuant to the safe harbor provisions of, the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical fact, including statements regarding
BioSpecifics' strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, expected revenue growth, shareholder
value, the commercial launch of XIAFLEX® for the treatment of
cellulite, the timing and occurrence of certain clinical trials,
the effect of recent management changes, and the assumptions
underlying or relating to such statements, are "forward-looking
statements." In some cases, these statements can be identified by
forward-looking words such as "expect," "plan," "anticipate,"
"potential," "estimate," "can," "will," "continue," "should,"
"believe," "schedule," "intend," the negative or plural of these
words, and other similar expressions. These forward-looking
statements are predictions based on the Company's current
expectations and its projections about future events and various
assumptions. These forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may be beyond
the Company's control, and which may cause the actual results,
performance, or achievements of BioSpecifics to be materially
different from future results, performance, or achievements
expressed or implied by such forward-looking statements. All
forward-looking statements included in this report are made as of
the date hereof, and are expressly qualified in their entirety by
this cautionary notice, including, without limitation, those risks
and uncertainties described in the Company's annual report on Form
10-K for the year ended December 31,
2018, and otherwise in its SEC reports and filings. Except
as may be required by law, BioSpecifics assumes no obligation to
update these forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-names-j-kevin-buchi-as-chief-executive-officer-300936191.html
SOURCE BioSpecifics Technologies Corp.